Multiparametric flow cytometric analysis in a breast cancer cell line (MCF-7)

Journal of Obstetrics and Gynaecology Research

Volumn 28, Issue 3, 2002, Pages 141-148

  Lee, Gui Se Ra ^a   Ryu, Ki Sung ^a   Rha, Jong Gu ^a   Kim, Soo Pyung ^a   Namkoong, Sung Eun ^a   Han, Ku Taek ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Cellular antigen; Cytokeratin; Fluorescein isothiocyanate; MCF 7 cell; Multiparametric flow cytometry; Phycoerythrin; Propidium iodide

Indexed keywords

CELL ANTIGEN; CYCLINE; CYTOKERATIN; DNA; FLUORESCEIN ISOTHIOCYANATE; FLUOROCHROME; GROWTH FACTOR RECEPTOR; MYC PROTEIN; PHYCOERYTHRIN; PROPIDIUM IODIDE; PROTEIN P53;

ALGORITHM; ANALYTICAL PARAMETERS; ANEUPLOIDY; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL LABELING; CELL POPULATION; CELL SPECIFICITY; CELL STRAIN MCF 7; COMPUTER PROGRAM; CONTROLLED STUDY; COVARIANCE; CYTOLOGY; DEVICE; DIPLOIDY; EPITHELIUM; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTER; FLUOROCHROME STAINING; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LASER; LYMPHOCYTE; METAPHASE; MIXED CELL CULTURE; NEOPLASM; ONCOGENE C ERB; PLOIDY; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; SOLID TUMOR; STAINING; STROMA CELL;

BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; PHYCOERYTHRIN; PROPIDIUM; STAINING AND LABELING; TUMOR CELLS, CULTURED;

EID: 0036592679     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1341-8076.2002.00005.x     Document Type: Article

References (48)

1. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia
2. Prognostic factors and treatment decisions in axillary-node-negative breast cancer
3. Consensus review of the clinical utility of DNA flowcytometry in colorectal cancer
4. DNA cytometry consensus conference
5. Guidelines for implementation of clinical DNA cytometry
6. Consensus review of the clinical utility of DNA cytometry in bladder cancer
7. Genetic alterations in prostate cancer
8. Assessing of sequential oncogene amplification in human breast cancer
9. Preferred genetic evolutionary sequences in human breast cancer: A case study
10. Genetic progression model for head and neck cancer: Implications for field cancerization
11. Simultaneous paired analysis by flow cytometry of surface markers, cytoplasmic antigens, or oncogene expression with DNA content
12. Protooncogene amplification and tumor ploidy in human ovarian neoplasms
13. Epidermal growth factor receptor in normal ovarian and benign ovarian tumors
14. Cell kinetics in human breast cancer. Comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry
15. Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers
16. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial
17. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma
18. Simultaneous three color detection of surface antigen (My7), intracellular antigen (c-myc), and DNA content using single laser flow cytometry
19. A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification
20. Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry
21. Improved staining method for the simultaneous flow cytofluorometric analysis of DNA content, S-phase fraction, and surface phenotype using single laser instrumentation
22. Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors
23. Multiparametric deoxyribonucleic acid and cell cycle analysis of breast carcinomas by flow cytometry: Clinicopathologic correlations
24. Cell kinetic analysis of mixed populations using three-color fluorescence flow cytometry
25. Simultaneous measurement of two cellular antigens and DNA using fluorescein-isothiocyanate, R-phycoerythrin, and propidium iodide on a standard FACScan
26. Two-color multiparametric method for flow cytometric DNA analysis of carcinomas using staining for cytokeratin and leukocyte-common antigen
27. Three parameter flow cytometric analysis for simultaneous detection of cytokeratin, proliferation associated antigens, and DNA content
28. Cell cycle specific inhibitors
29. Flow cytometric measurements of DNA and other cell components in human tumors: A critical appraisal
30. Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology
31. Multiparametric evaluation of low cytometric synthesis phase fraction determination in dual-labelled breast carcinomas
32. Cell size, DNA, and cytokeratin analysis of human head and neck tumors by flow cytometry
33. Nuclear distribution of the Ki-67 antigen during the cell cycle: Comparison with growth fraction in human breast cancer cells
34. Flow cytometric analysis of proliferation associated nuclear antigens using washless staining of unfixed cells
35. Cell cycle-related proteins: A flow cytofluorometric study in human tumors
36. Intranuclear co-location of newly replicated DNA and PCNA by simultaneous immunofluorescent labeling and confocal microscopy in MCF-7 cells
37. Nonisotope quantification of mRNA using a novel RNAse protection assay: Measurement of erbB-2 mRNA in tumor cells lines
38. Clinical and pathologic significance of the c-erbB/2 (HER-2/neu) oncogene
39. Prognostic significance of c-erbB/2 mRNA in ovarian carcinoma
40. ERBB-2 (HERs/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer
41. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo
42. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells
43. p53 gene mRNA expression and chromosome 17p allele loss in breast cancer
44. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance
45. c-myc oncogene product p62c-myc in ovarian mucinous neoplasm: Immunohistochemical study correlated with malignancy
46. Effects of tamoxifen and retinoic acid on cell growth and c-myc gene expression in human breast and cervical cancer cells
47. Analysis of human breast cancer nuclear proteins binding to the promoter elements of the c-myc gene
48. Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells